,datetime,sentence,positive,negative,neutral,global_sentiment,avg_sentiment
0,2013-10-16 08:06:00,St. Jude Medical Inc. 's ( STJ ) third-quarter adjusted earnings per share of 90 cents beat the Zacks Consensus Estimate by a penny.,0.9428253173828125,0.033112332224845886,0.024062342941761017,positive,0.9097129702568054
1,2013-10-16 08:06:00,It also surpassed the year-ago earnings of 83 cents by 8.4%.,0.9518077373504639,0.028667042031884193,0.019525326788425446,positive,0.9231407046318054
2,2013-10-16 08:06:00,Adjusted earnings were at the higher end of the company's third-quarter guidance of 88-90 cents a share.,0.7748519778251648,0.0282343327999115,0.1969137191772461,positive,0.7466176748275757
3,2013-10-16 08:06:00,Net income (including one-time items) for the quarter surged 48.9% to $262 million or 90 cents a share from $176 million or 56 cents per share in the year-ago quarter.,0.9508817791938782,0.03120828978717327,0.017909975722432137,positive,0.919673502445221
4,2013-10-16 08:06:00,"Revenues inched up 1% (3% in constant currency) year over year to $1,338 million in the third quarter and exceeded the Zacks Consensus Estimate of $1,321 million.",0.959696352481842,0.021865595132112503,0.018437985330820084,positive,0.9378307461738586
5,2013-10-16 08:06:00,Unfavorable foreign currency lowered total revenues by $26 million.,0.01630423590540886,0.9722335338592529,0.011462191119790077,negative,-0.9559292793273926
6,2013-10-16 08:06:00,"Revenues in the U.S. (48.3% of total revenues) and in the international markets increased 1.1% and 0.7% to $646 million and $692 million, respectively in the reported quarter.",0.9552209377288818,0.019742801785469055,0.025036348029971123,positive,0.935478150844574
7,2013-10-16 08:06:00,Gross margin declined by a whopping 200 basis points (bps) to 71.2% in the quarter from 73.2% in the prior-year quarter.,0.018414532765746117,0.9742825627326965,0.007302858866751194,negative,-0.9558680057525635
8,2013-10-16 08:06:00,"Selling, general and administrative expenses decreased 0.9% to $452 million.",0.018785055726766586,0.9713677167892456,0.009847288951277733,negative,-0.9525826573371887
9,2013-10-16 08:06:00,Research and development expenses grew 1.2% to $172 million in the quarter.,0.9387296438217163,0.03064436838030815,0.030626047402620316,positive,0.908085286617279
10,2013-10-16 08:06:00,"However, operating margin rose 570 bps to 23.4% from 17.7% a year ago, mainly on account of lower special charges.",0.9585246443748474,0.026787376031279564,0.014688009396195412,positive,0.9317372441291809
11,2013-10-16 08:06:00,Revenues from the Cardiac Rhythm Management (CRM) division - St. Jude's mainstay - slid 1% (flat in constant currency) to $682 million.,0.02309933677315712,0.9675082564353943,0.009392344392836094,negative,-0.9444088935852051
12,2013-10-16 08:06:00,This represents a marked improvement from the 4% decline reported in the second quarter of 2013.,0.9326720237731934,0.046593401581048965,0.020734496414661407,positive,0.8860785961151123
13,2013-10-16 08:06:00,"ICD revenues improved 1% (up 2% constant currency) to $418 million, while pacemaker sales dropped 5% (down 3% in constant currency) to $264 million.",0.881104588508606,0.09487265348434448,0.024022778496146202,positive,0.7862319350242615
14,2013-10-16 08:06:00,The Atrial Fibrillation division is the only business that is giving higher returns compared to the other segments.,0.7972509860992432,0.01717812567949295,0.1855708211660385,positive,0.7800728678703308
15,2013-10-16 08:06:00,Revenues from this division climbed 7% (up 10% in constant currency) year over year to $235 million.,0.9563663601875305,0.018636571243405342,0.0249970443546772,positive,0.9377297759056091
16,2013-10-16 08:06:00,Revenues from the Cardiovascular franchise inched up 1% (4% in constant currency) to $317 million.,0.9578647613525391,0.019182903692126274,0.022952377796173096,positive,0.9386818408966064
17,2013-10-16 08:06:00,"Within Cardiovascular, vascular product revenues dipped 1% to $168 million while structural heart product revenues grew 3% to $149 million.",0.01750039868056774,0.9725828766822815,0.009916763752698898,negative,-0.9550824761390686
18,2013-10-16 08:06:00,Neuromodulation revenues were up roughly 3% both in reported and constant currency bases to $104 million in the quarter.,0.9559210538864136,0.018761103972792625,0.025317763909697533,positive,0.9371599555015564
19,2013-10-16 08:06:00,"St. Jude exited the third quarter of 2013 with cash and cash equivalents of $1,245 million, 4.3% higher than $1,194 million as of Dec 29, 2012.",0.8884870409965515,0.022590871900320053,0.08892200887203217,positive,0.8658961653709412
20,2013-10-16 08:06:00,"Long-term debt increased 33.5% to $3,403 million from $2,550, as of Dec 29, 2012.",0.9502152800559998,0.015987874940037727,0.03379681333899498,positive,0.9342274069786072
21,2013-10-16 08:06:00,STJ has provided its forecast for the fourth quarter and has also revised its earnings guidance for 2013.,0.06476283073425293,0.02475729212164879,0.9104799032211304,neutral,0.04000553861260414
22,2013-10-16 08:06:00,"The company expects total revenues for full year 2013 to be in the range of $5,394 million to $5,474 million.",0.049315400421619415,0.00557586457580328,0.9451087117195129,neutral,0.04373953491449356
23,2013-10-16 08:06:00,"Further, the company raised its adjusted earnings expectations for the year to the band of $3.72-$3.74 from the earlier range of $3.70-$3.73.",0.9378207921981812,0.017791124060750008,0.0443880595266819,positive,0.9200296401977539
24,2013-10-16 08:06:00,"The current Zacks Consensus Estimate for 2013 revenues and earnings are pegged at $5,450 million and $3.72 per share.",0.02109992690384388,0.019254546612501144,0.9596455097198486,neutral,0.0018453802913427353
25,2013-10-16 08:06:00,"For the fourth quarter, St. Jude anticipates revenues to be in the range of $1,315 million to $1,395 million and adjusted earnings between 95 and 97 cents a share.",0.053754571825265884,0.010595698840916157,0.9356497526168823,neutral,0.0431588739156723
26,2013-10-16 08:06:00,"The Zacks Consensus Estimate for revenues and earnings for the fourth quarter stands at $1,388 million and $96 cents per share, respectively.",0.026990143582224846,0.03322839364409447,0.9397814869880676,neutral,-0.006238250061869621
27,2013-10-16 08:06:00,"We are impressed with STJ's third quarter results, which beat estimates at both fronts.",0.9473696947097778,0.01815531961619854,0.034474968910217285,positive,0.929214358329773
28,2013-10-16 08:06:00,"Moreover, the company's raised guidance is encouraging.",0.9193115830421448,0.013495225459337234,0.06719323247671127,positive,0.905816376209259
29,2013-10-16 08:06:00,New products from fresh acquisitions should further propel the top line in the near term.,0.9432947635650635,0.015592532232403755,0.041112691164016724,positive,0.9277022480964661
30,2013-10-16 08:06:00,We have also noted sequential gradual improvement in the beleaguered core CRM business.,0.9488022923469543,0.015685327351093292,0.03551240637898445,positive,0.9331169724464417
31,2013-10-16 08:06:00,St. Jude currently carries a Zacks Rank #2 (Buy).,0.3178336024284363,0.02293192222714424,0.6592345237731934,neutral,0.29490166902542114
32,2013-10-16 08:06:00,"Other medical products companies such as Resmed Inc. ( RMD ), Bio-Rad Laboratories, Inc. ( BIO ) and Boston Scientific Corp. ( BSX ) are also expected to do well.",0.9390252232551575,0.017649726942181587,0.04332499951124191,positive,0.9213755130767822
33,2013-10-16 08:06:00,"While RMD and BIO carry a Zacks Rank #1 (Strong Buy), BSX has a Zacks Rank #2 (Buy).",0.37295499444007874,0.02715905010700226,0.5998860001564026,neutral,0.3457959294319153
34,2013-10-16 08:06:00,To read this article on Zacks.com click here.,0.017961200326681137,0.01924508437514305,0.9627937078475952,neutral,-0.001283884048461914
35,2013-10-16 08:06:00,"The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.",0.010204566642642021,0.015637893229722977,0.9741575717926025,neutral,-0.0054333265870809555
